2607.HKライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (2 5月 2024 @ 17:08):

Stats
本日の出来高	2.02M
平均出来高	2.41M
時価総額	57.43B
EPS	HKD0.320 ( 2023-10-27 )
次の収益日	( HKD0 ) 2024-06-28
Last Dividend	HKD0.664 ( 2023-07-18 )
Next Dividend	HKD0 ( N/A )
P/E	10.09
ATR14	HKD0.0200 (0.18%)

ボリューム相関

長: -0.23 (neutral)

短: -0.96 (very strong negative)

Signal:(38.42) Neutral

Shanghai Pharmaceuticals 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Shanghai Pharmaceuticals 相関 - 通貨/商品

0.55
( weak )

0.38
( neutral )

0.00
( neutral )

0.65
( weak )

-0.54
( weak negative )

-0.43
( neutral )

Shanghai Pharmaceuticals 財務諸表

Annual	2023
収益:	HKD260.30B
総利益:	HKD31.33B (12.04 %)
EPS:	HKD1.020

FY	2023
収益:	HKD260.30B
総利益:	HKD31.33B (12.04 %)
EPS:	HKD1.020

FY	2022
収益:	HKD231.98B
総利益:	HKD30.49B (13.14 %)
EPS:	HKD1.610

FY	2021
収益:	HKD215.82B
総利益:	HKD28.54B (13.23 %)
EPS:	HKD1.790

Financial Reports:

No articles found.

Shanghai Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.984 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.664 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Shanghai Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.96 - good (99.58%) | Divividend Growth Potential Score: 5.66 - Stable (13.11%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.196	2012-06-14
Last Dividend	HKD0.664	2023-07-18
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	13	--
Total Paid Out	HKD5.57	--
Avg. Dividend % Per Year	0.00%	--
Score	2.97	--
Div. Sustainability Score	9.96
Div.Growth Potential Score	5.66
Div. Directional Score	7.81	--

Next Divdend (Est)
(2024-07-11)

HKD0.720 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.97

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
9600.HK	No Dividend Player	2023-06-14	Insufficient data to determine frequency	0.00%
2111.HK	Ex Dividend Knight	2023-09-13	Annually	0.00%
1117.HK	Ex Dividend Junior	2023-06-08	Sporadic	0.00%
0189.HK	Ex Dividend Junior	2023-06-14	Annually	0.00%
3813.HK	Ex Dividend Junior	2023-09-12	Sporadic	0.00%
1705.HK	Ex Dividend Knight	2023-09-25	Annually	0.00%
0732.HK	Ex Dividend Knight	2023-11-10	Annually	0.00%
2285.HK	Ex Dividend Junior	2023-06-06	Annually	0.00%
1271.HK	Ex Dividend Junior	2023-08-10	Semi-Annually	0.00%
0327.HK	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0144	1.500	9.71	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0174	1.200	9.42	10.00	[0 - 0.3]
returnOnEquityTTM	0.0553	1.500	-0.497	-0.745	[0.1 - 1]
payoutRatioTTM	1.029	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.336	0.800	8.32	6.65	[1 - 3]
quickRatioTTM	1.058	0.800	8.48	6.78	[0.8 - 2.5]
cashRatioTTM	0.240	1.500	9.78	10.00	[0.2 - 2]
debtRatioTTM	0.226	-1.500	6.23	-9.35	[0 - 0.6]
interestCoverageTTM	4.07	1.000	9.60	9.60	[3 - 30]
operatingCashFlowPerShareTTM	2.14	2.00	9.29	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.281	2.00	9.36	10.00	[0 - 20]
debtEquityRatioTTM	0.701	-1.500	7.20	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.116	1.000	-1.395	-1.395	[0.2 - 0.8]
operatingProfitMarginTTM	0.0287	1.000	-1.425	-1.425	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.160	1.000	-0.223	-0.223	[0.2 - 2]
assetTurnoverTTM	1.215	0.800	5.23	4.19	[0.5 - 2]
Total Score				9.96

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	9.79	1.000	9.11	0	[1 - 100]
returnOnEquityTTM	0.0553	2.50	-0.319	-0.745	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.281	2.00	9.57	10.00	[0 - 30]
dividendYielPercentageTTM	6.57	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.14	2.00	9.29	10.00	[0 - 30]
payoutRatioTTM	1.029	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	2.12	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0297	1.000	-1.757	0	[0.1 - 0.5]
Total Score				5.66

Shanghai Pharmaceuticals

Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People's Republic of China. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including oncology, cerebrocardiovascular, CNS, general infection, immunology, digestive and metabolism, and respiratory. It provides approximately 700 varieties of drugs. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores; online drug business; and provision of consulting services, assets management operations, as well as clinical trials, medical aid, physicians and patients' education, e-prescription management, and remote and cloud hospitals. Further, the company manufactures and trades in medicines. It operates approximately 2,000 retail chain pharmacies in 24 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.